Online First

Original Article
Trends in disease indications for hematopoietic stem cell transplantation in the Asia-Pacific region: A report of the Activity Survey 2017 from APBMT
Minako Iida1, Kaiyan Liu2, Xiao Jun Huang2, Wu Depei3, Yachiyo Kuwatsuka4, Joon Ho Moon5, Anthony Dodds6, Leonie Wilcox7, Bor-Sheng Ko8, Amir Ali Hamidieh9, Kim Wah Ho10, Artit Ungkanont11, Aloysius Ho12, Tasneem Farzana13, Joycelyn Sim14, Huynh Van Man15, Mafruha Akter16, Prasad Abeysinghe17, Marjorie Rose Bravo18, Aye Aye Gyi19, Bishesh Sharma Poudyal20, Khishigjargal Batshkh21, Alok Srivastava22, Shinichiro Okamoto23, Yoshiko Atsuta24,25,

1Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan

2Department of Hematology, Peking University Institute of Hematology, Beijing, China

3Department of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China

4Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan

5Division of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea

6St. Vincent's Pathology, St. Vincent's Health Network, Sydney, and Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia

7Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia

8Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

9Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

10Department of Hematology, Hospital Ampang, Ampang Selangor, Malaysia

11Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand

12Department of Haematology, Singapore General Hospital, Singapore, Singapore

13Department of Clinical Haematology, National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan

14Department of Medicine, Queen Mary Hospital, Hong Kong

15Stem Cell Transplantation Department, Blood Transfusion and Hematology Hospital, Ho Chi Minh, Vietnam

16Bone marrow transplant unit, Department of Hematology, Dhaka Medical College and Hospital, Dhaka, Bangladesh

17Department of Oncology, National Cancer Institute, Maharagama, Sri Lanka

18St Luke's Medical Center Quezon City, IM Hematology/Blood and Marrow Transplant, Quezon, the Philippines

19Department of Clinical Haematology, North Okkalapa General Hospital, Yangon, Myanmar

20Civil Service Hospital, Clinical Hematology and Bone Marrow Transplant Unit, Kathmandu, Nepal

21Bone and Marrow transplantation team, Hematology Department, National First Central Hospital of Mongolia, Ulaanbaatar, Mongolia

22Department of Haematology, Christian Medical College Hospital, Vellore, India

23Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

24Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Nagakute, Japan

25Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan

Asia-Pacific region, hematopoietic stem cell transplant, disease indication
Submitted:March 6, 2022
Accepted:March 28, 2022
Published online:July 8, 2022


The Asia-Pacific Blood and Marrow Transplantation Group (APBMT) has been conducting annual surveys on the activity of hematopoietic stem cell transplants since 2007. The APBMT Data Center collected the following data in 2017. A total of 21,504 transplants were registered from 733 transplant centers of 20 countries/regions in the Asia-Pacific (AP) region. Five countries/regions comprised 89.4% of all transplants – China (6,979), Japan (5,794), South Korea (2,626), India (2,034), and Australia (1,789). The number of centers in these five countries/regions also comprised 88.9% of all centers: Japan (373), China (123), India (66), Australia (45), and South Korea (44). The overall ratio between autologous and allogeneic transplants was 37.0% and 63.0%, respectively, but the ratios varied significantly among countries/regions. Autologous transplants have surpassed allogeneic transplants in Thailand, Australia, Vietnam, New Zealand, Singapore, and Iran. In contrast, the proportion of allogeneic transplants comprised over 70% of all transplants in Pakistan, China, and Hong Kong. These ratios were compared by the Data Center among countries/regions that performed more than 50 transplants. The proportion of related and unrelated transplants also differed among countries/regions. The number of unrelated transplants was more than related ones in Japan (2,551 vs. 1,202) and Australia (329 vs. 291), whereas more than 80% of all transplants were related transplants in Malaysia (90.9%), India (89.5%), Iran (87.2%), Vietnam (85.7%), China (80.9%), and Thailand (80.6%). All transplant activities were related transplants in Pakistan, the Philippines, Myanmar, and Nepal, and no allogeneic transplants were performed in Bangladesh and Mongolia. Regarding the indications for transplants, acute myeloid leukemia (AML) was the most common disease for allogeneic transplant (4,759, 35.1% of allogeneic transplants), while plasma cell disorder (PCD) was the most common disease for autologous transplant (3,701, 27.3% of all autologous transplants). Furthermore, the number of transplants for hemoglobinopathy has steeply increased in this region compared with the rest of disease indications (677, 3.1% of all transplants). APBMT covers a broad area globally, including countries/regions with diverse disease distribution, development of HSCT programs, population, and economic power. Consistent and continuous activity surveys considering those elements in each country/region revealed the HSCT field's diverse characteristics and background factors in this region.


Online ISSN:2432-7026